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medical technologies and procedures conducted by the Medical Services Advisory 
Committee (MSAC). METHODS: Data collection was over a nine month period 
(August 2008 to April 2009). Twenty in-depth, semi-structured interviews were con-
ducted with four stakeholders groups: 1) MSAC committee members and evaluators; 
2) academic and health technology assessment experts; and 3) medical industry rep-
resentatives and (iv) specialists. Interviews were digitally recorded, transcribed verba-
tim and coded using a constant comparative method. RESULTS: The current MSAC 
decision-making process was described as generally fair and transparent. However 
stakeholder’s perceived that the burden of proof does vary from the evaluation of 
pharmaceuticals where “it’s largely resting on the sponsor”. It is perceived that the 
effectiveness of pharmaceuticals per se can be identiﬁed but that of medical devices 
and techniques has to be placed within the context of the specialist providing the 
service and setting. The MSAC process is described as more ﬂexible, “intuitive” and 
“idiosyncratic” due to the nature of the technologies being appraised (diagnostics, 
devices, procedures) and the different types of applicants. Unlike pharmaceuticals 
these technologies are more likely to be introduced and diffused in the Australian 
health care system without being evaluated by MSAC. CONCLUSIONS: The results 
of this study suggest that stakeholder’s perceived that the current process for evaluat-
ing non pharmaceutical technologies differs signiﬁcantly to that of pharmaceuticals. 
This was thought to be partially as a result of the intrinsic differences in the items 
under evaluation and partially due to the different institutional arrangements under 
which the evaluations take place. While differences in assessment for the former reason 
are generally justiﬁed, differences stemming from the latter may require consideration 
of what constitutes best practice, and possible amendment of the process.
PHP70
HTA INSITE: ANALYSIS OF AN ON-LINE DATABASE OF ALL NICE 
SUBMISSIONS AND DECISIONS
Niziol C, Howard S, Warner J
Abacus International, Bicester, Oxfordshire, UK
OBJECTIVES: HTA inSite is an on-line, subscription-based database of all NICE 
Technology Appraisals (TAs). It includes information relating to submitted evidence, 
appraisal process and ﬁnal decision and enables assessment of associated trends. 
METHODS: An academic steering group designed and agreed the data extraction 
protocol. A team of reviewers conducted the initial data extraction, which was vali-
dated by a second reviewer. Historical extraction is complete, with on-going TAs 
extracted on a monthly basis. RESULTS: A total of 161 TAs have been extracted to 
date, 4 of which were terminated, resulting in 157 complete TAs relating to 300 
technologies. Of these, 52% were awarded a restricted decision, 33% were fully rec-
ommended and 15% rejected. Of the three most commonly appraised disease areas 
(cancer, cardiovascular (CVS), central nervous system (CNS)); CVS technologies were 
least commonly rejected by NICE (3% vs. 17% for both cancer and CNS). Of the 
four most commonly used assessment groups (Shefﬁeld, York, Southampton and Bir-
mingham); technologies assessed by Shefﬁeld were most commonly rejected (28%) 
and those by York were least commonly rejected (3%). Technologies supported by a 
patient submission were less commonly rejected than those without (14% vs. 33%). 
A total of 30 TAs (19%) resulted in an appeal and in 5 (17%) of these cases the appeal 
was upheld completely, with 3 (10%) being partially upheld. HTA inSite also allows 
detailed analysis of individual TAs and cross-comparison between TAs as well as 
identifying trends between submitted evidence (acquisition costs, budget impact, cost-
effectiveness and clinical effectiveness) and ﬁnal outcome. These additional analyses 
will be further explored in the podium presentation. CONCLUSIONS: HTA inSite is 
a useful tool for anyone interested in understanding the relationship between submit-
ted evidence and ultimate NICE decision. The HTA inSite format may be useful for 
other HTA bodies, depending on the public availability of relevant information.
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OBJECTIVES: To compare HTA recommendations of Agency for Health Technology 
Assessment (AHTAPoL) in Poland with HTA recommendations of the Scottish Medi-
cines Consortium (SMC) by drug technology submitted to both Agencies for the same 
indication. METHODS: From 66 submissions, appraised by AHTAPol in the period 
January 1–December 31 2008, only drug technologies submitted to SMC for the same 
indication, were selected. Where there was more than one submission to a single 
Agency for the same indication, the most recent outcome was included. Appraisals 
were grouped into positive and negative recommendations. The clinical and non-
 clinical reasons for rejection of use were studied. The positive recommendations were 
divided into guidance with major, minor and without restrictions. RESULTS: Forty-
eight drug technologies were appraised by both Agencies. Similar recommendations 
were issued in 31 cases. A contradictory guidance was given at 17 occasions. Negative 
recommendations constituted 40% and 25% of all HTA appraisals issued by AHTAPol 
and SMC respectively. While clinical reasons prevailed in Poland (14 of 19 cases), 
poor economic data was the most often stated reason for negative guidance in Scotland 
(7 of 12 cases). Positive recommendations constituted 60% and 75% of all HTA 
appraisals issued by AHTAPol and SMC respectively. Major restrictions prevailed in 
both countries: 22 of 29 and 23 of 36 in Poland and Scotland respectively. AHTAPol 
issued 6 recommendations with minor restrictions. There were no such cases in Scot-
land. At the same time, SMC issued 13 positive recommendations without restrictions. 
AHTAPol generated only one such guidance. CONCLUSIONS: The positive HTA 
recommendations were more common in Scotland than in Poland in the group of drug 
technologies submitted to both Agencies for the same indication. While a clinical 
aspect was the most common reason for rejection in Poland, SMC pointed out mainly 
economic issues in their negative recommendations.
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OBJECTIVES: The National Centre for Pharmacoeconomics (NCPE) appraises the 
cost-effectiveness of new and existing technologies (medicines, diagnostics and devices) 
which may entail a high budget impact to the health system, in response to requests 
from the Health Service Executive (HSE). In the case of new medicines, assessments 
may be conducted prior to reimbursement application but must be completed within 
90 days. We describe the pharmacoeconomic evaluation process in Ireland and provide 
examples of recent appraisals and the subsequent impact on pricing and reimburse-
ment decisions. METHODS: The pharmacoeconomic appraisals conducted by the 
NCPE between September 2006 and May 2009 were reviewed. The NCPE recom-
mendations and subsequent reimbursement decisions by the HSE were recorded. The 
duration of the pharmacoeconomic process and the time from marketing authorisation 
to reimbursement was estimated. The budget impact assessments from the pharma-
ceutical companies were reviewed and compared for consistency. RESULTS: The 
NCPE conducted fourteen single technology appraisals during the study period. 
There is only one example of an existing medicine where cost-effectiveness data was 
requested to ensure continued reimbursement. All other evaluations were for newly 
licensed medicines. Eight of the medicines assessed were either recommended as a 
cost-effective use of resources or recommended with certain restrictions, and were 
funded by the HSE. Of the six medicines that were not considered cost-effective, two 
were reimbursed after a price reduction was negotiated, two were not reimbursed 
and the decision for the remaining two medicines is pending. The average duration of 
the pharmacoeconomic process was 2.7 months. The average time from marketing 
authorisation to reimbursement was 7 months. The review of budget impact assess-
ments highlighted a high degree of variability between submissions. CONCLUSIONS: 
The ﬁndings of this review demonstrate the efﬁciency of the pharmacoeconomic 
process and the acceptance of the NCPE recommendations by the HSE for pricing and 
reimbursement decisions.
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OBJECTIVES: Our objective was to assess whether 15 Key Principles, previously 
proposed by our group—the International Working Group for HTA Advancement—
could be applied to health technology assessment (HTA) programs in different jurisdic-
tions and across a range of organizations and perspectives. METHODS: We 
investigated the extent to which 14 HTA organizations around the world implicitly 
support and implement the Key Principles. By “support,” we meant that the organiza-
tion backs the principle in written guidelines or other form, regardless of whether they 
actually follow it. By “implemented,” we meant that published reports and decisions 
based on reports were consistent with the principles. The HTA organizations were 
chosen to include examples of both established and emerging entities with different 
roles and objectives. They include HTA organizations in Australia (PBAC), Brazil 
(ANVISA), Canada (CADTH), Germany (DAHTA@DIMDI, IQWiG), Korea (HIRA), 
Sweden (TLV, SBU), Taiwan (CDE), the UK (NICE), and United States (Blue Cross/
Blue Shield, CMS, DERP, Wellpoint). RESULTS: There is considerable variation in 
practices across the HTA organizations. Many of the organizations support and imple-
ment certain principles, such as being explicit about their HTA goals and scope; con-
sidering a wide range of evidence and outcomes; and seeking all available data. Other 
principles, such as taking a full societal perspective; having a clear system for setting 
priorities; explicitly characterizing uncertainty surrounding estimates; monitoring the 
implementation of HTA ﬁndings; and considering the generalizability and transfer-
ability of results receive much less backing. There is also variation in the degree to 
which organizations incorporate appropriate methods for assessing costs and beneﬁts. 
CONCLUSIONS: There is considerable room for improvement for HTA organiza-
tions to adopt principles identiﬁed to reﬂect good HTA practices. A broader discussion 
is needed on principles that do not receive widespread support and implementation.
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OBJECTIVES: Wireless telecommunication technology is commonplace in today’s 
life including health care environment. Critical care medical equipment such as      
